1. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Issue 11 (November 2017) Authors: Balar, Arjun V; Castellano, Daniel; O'Donnell, Peter H; Grivas, Petros; Vuky, Jacqueline; Powles, Thomas; Plimack, Elizabeth R; Hahn, Noah M; de Wit, Ronald; Pang, Lei; Savage, Mary J; Perini, Rodolfo F; Keefe, Stephen M; Bajorin, Dean; Bellmunt, Joaquim Journal: Lancet oncology Issue: Volume 18:Issue 11(2017:Nov.) Page Start: 1483 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Issue 6 (June 2022) Authors: Motzer, Robert; Porta, Camillo; Alekseev, Boris; Rha, Sun Young; Choueiri, Toni K; Mendez-Vidal, Maria Jose; Hong, Sung-Hoo; Kapoor, Anil; Goh, Jeffrey C; Eto, Masatoshi; Bennett, Lee; Wang, Jinyi; Pan, Jie Janice; Saretsky, Todd L; Perini, Rodolfo F; He, Cixin Steven; Mody, Kalgi; Cella, David Journal: Lancet oncology Issue: Volume 23:Issue 6(2022) Page Start: 768 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Issue 7 (July 2021) Authors: Lee, Chung-Han; Shah, Amishi Yogesh; Rasco, Drew; Rao, Arpit; Taylor, Matthew H; Di Simone, Christopher; Hsieh, James J; Pinto, Alvaro; Shaffer, David R; Girones Sarrio, Regina; Cohn, Allen Lee; Vogelzang, Nicholas J; Bilen, Mehmet Asim; Gunnestad Ribe, Sara; Goksel, Musaberk; Tennøe, Øyvind Kroh... Journal: Lancet oncology Issue: Volume 22:Issue 7(2021) Page Start: 946 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Issue 3 (March 2023) Authors: Choueiri, Toni K; Eto, Masatoshi; Motzer, Robert; De Giorgi, Ugo; Buchler, Tomas; Basappa, Naveen S; Méndez-Vidal, María José; Tjulandin, Sergei; Hoon Park, Se; Melichar, Bohuslav; Hutson, Thomas; Alemany, Carlos; McGregor, Bradley; Powles, Thomas; Grünwald, Viktor; Alekseev, Boris; Rha, Sun Youn... Journal: Lancet oncology Issue: Volume 24:Issue 3(2023) Page Start: 228 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Issue 2 (February 2017) Authors: Plimack, Elizabeth R; Bellmunt, Joaquim; Gupta, Shilpa; Berger, Raanan; Chow, Laura Q M; Juco, Jonathan; Lunceford, Jared; Saraf, Sanatan; Perini, Rodolfo F; O'Donnell, Peter H Journal: Lancet oncology Issue: Volume 18:Issue 2(2017:Feb.) Page Start: 212 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗